LoadingLoadingLoadingThe quick read
Latest quote·Oct 13
Net selling: insiders sold $29.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $17K to $80K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $29.9M and bought $0 of IQV stock on the open market in the 90 days to Oct 16, 2026, according to SEC Form 4 filings. The largest was Bousbib, Ari (See Remarks), who sold $26.1M. The latest filing was on Sep 4, 2026.
Rep. Kevin Hern (R) sold $15K to $50K on Sep 14, 2026, disclosed 11 days later. Rep. Kevin Hern (R) sold $1K to $15K on Sep 8, 2026, disclosed 17 days later. Rep. Kevin Hern (R) sold $1K to $15K on Sep 3, 2026, disclosed 22 days later. In total, 1 member disclosed 3 IQV trades with trade dates in the last 180 days, filed a median 17 days after trading.
This summary uses filings available on Oct 16, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (2)
Balyasny
$134.9M
added
D.E. Shaw
$90.1M
bought
Sells/Trims (1)
Viking Global
$139.6M
sold
No tracked top-trader positions in IQV right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 28, 2026
Financial period
Q2 2026
Adjusted EPS
$3.03 expected
Revenue
No comparable estimate
Full-year 2026 guidance
$17.27B to $17.48B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 28, 2026 | $3.15 / $3.03Yahoo Finance | +3.94% beat | $4.37B / Unavailable | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $2.90 / $2.82Yahoo Finance | +2.96% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 5, 2026 | $3.42 / $3.40Yahoo Finance | +0.69% in line | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $3.00 / $2.98Yahoo Finance | +0.81% in line | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 22, 2025 | $2.81 / $2.77Alpha Vantage | +1.44% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 6, 2025 | $2.70 / $2.63Alpha Vantage | +2.66% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 6, 2025 | $3.12 / $3.11Alpha Vantage | +0.32% in line | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | $2.84 / $2.81Alpha Vantage | +1.07% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 15, 2026
EPS expected
$3.22 to $3.54
Revenue expected
16 analysts
Last 30 days
Analysts raising estimates
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $4.10B | $4.36B | $4.15B | $4.37B |
| Cost of what it sold | $2.73B | $4.07B | $2.80B | $2.93B |
| Gross profit | $1.37B | $292.0M | $1.35B | $1.44B |
| What it spent | ||||
| Sales and admin | $514.0M | $468.0M | $502.0M | $574.0M |
| Other operating costs | $306.0M | -$908.0M | $339.0M | $355.0M |
| Total operating expenses | $820.0M | -$440.0M | $841.0M | $929.0M |
| What was left | ||||
| Operating profit | $553.0M | $732.0M | $514.0M | $506.0M |
| Interest on debt | $189.0M | $193.0M | $192.0M | $197.0M |
| Profit before tax | $408.0M | $572.0M | $328.0M | $301.0M |
| Tax | $76.0M | $58.0M | $59.0M | $60.0M |
| Net profit | $331.0M | $514.0M | $274.0M | $256.0M |
| EBITDA | $883.0M | $1.05B | $808.0M | $790.0M |
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Thermo Fisher Scientific (TMO) Expands Drug Development Services, Is The Stock Fully Valued?
NeutralOct 15VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
Leans bullishOct 14Stifel Nicolaus Adjusts IQVIA Holdings Price Target to $303 From $276
BullishOct 14JPMorgan Adjusts Price Target on IQVIA Holdings to $295 From $285
Leans bullishOct 14Four Veeva tools will be standard across IQVIA's clinical studies
BullishOct 13IQVIA Holdings Inc. (IQV) Key Financial Ratios – Valuation, Profitability & More
NeutralOct 10IQVIA Holdings Inc. Common Stock (IQV) Stock Price Today: $259.88
NeutralOct 10Charles River Laboratories International, Inc. (CRL) stock price, news, quote and history
NeutralOct 1032 macro signals shaping IQV right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
